Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 234

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 234
---
 ($)(3)    |            ​ 
 compensation | ​ 
 ​ 
 ​ | ​     
 ​     
 Total 
 ($)   |       ​ 
       ​ |
|:-------------------------------------|:--|-----:|:--|:-------|--------:|:-------|:------|--------:|:-------|:-------|--------:|:--|:----------|-------------:|:--|:------|--------:|
| Imran Alibhai, Ph.D.                 |   | 2024 | ​ | $      | 551,050 | ​      | $     | 275,525 |        | ​      |       — | ​ | $         |       30,755 |   | $     | 857,330 |
| Chief Executive Officer and Director |   | 2023 | ​ | $      | 535,000 | ​      | $     | 267,500 |        | ​      |       — | ​ | $         |       28,757 | ​ | $     | 831,257 |
| John Kauh, M.D.                      |   | 2024 | ​ | $      | 412,000 | ​      | $     | 123,600 |        | ​      |       — | ​ | $         |       30,230 | ​ | $     | 565,830 |
| Chief Medical Officer                |   | 2023 | ​ | $      | 369,445 | (4)  ​ | $     | 135,466 | (2)  ​ | $      | 288,455 | ​ | $         |       25,989 | ​ | $     | 819,355 |
| Dan Conn, J.D., M.B.A.               |   | 2024 | ​ | $      | 381,100 | ​      | $     | 171,495 | ​      |        |       — | ​ |           |            — | ​ | $     | 552,595 |
| Chief Financial Officer              |   | 2023 | ​ | $      | 370,000 | ​      | $     | 111,000 | ​      |        |       — | ​ |           |            — | ​ | $     | 481,000 |

| (1) | Amounts reflect the full grant-date fair value of options awards granted during 2023 computed in accordance with Financial Accounting Standards Board (“F